Personalized Autologous Transplant

Personalized Autologous Transplant for Multiple Myeloma

What's the purpose of the trial?

This phase I trial studies the best dose and side effects of melphalan in treating patients with multiple myeloma who are undergoing stem cell transplant. 

Trial status

Accepting patients

Phase
Phase 1
Enrollment
90
Last Updated

Participating Centers

There are 2 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • Melphalan is a chemotherapy medication used in the treatment of different cancers.
  • Autologous Stem Cell Transplant is a type of stem cell transplant that utilizes the patient's own pre-collected stem cells to rescue the bone marrow from the toxic effects of very high dose chemotherapy.
  • Lenalidomide is an oral immunomodulatory drug that may help the immune system kill cancer cells. It may also prevent the growth of new blood vessels that tumors need to grow.
  • Personalized Vaccine Therapy is in development to treat certain kinds of cancer. Personalized Vaccines are made specifically for individual patients, and researchers think they can work by training the patients T-cells to recognize and attack their specific cancer cells.

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

Melphalan-Based Autologous Transplant

Accepting patients

Personalized Vaccine + Lenalidomide

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print this trial to share with your doctor.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.